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Chien-Fen Ku2, Guang-Yaw Liu5 and Hui-Chih Hung1,6
Cutaneous melanoma is the most life-threatening neoplasm of the skin, accounting for most of the skin cancer
deaths. Accumulating evidence suggests that targeting metabolism is an appealing strategy for melanoma therapy.
Mitochondrial NAD(P)þ–dependent malic enzyme (ME2), an oxidative decarboxylase, was evaluated for its
biological significance in cutaneous melanoma progression. ME2 mRNA and protein expression significantly
increased during melanoma progression, as evidenced by Gene Expression Omnibus analysis and immuno-
histochemistry on clinically annotated tissue microarrays, respectively. In addition, ME2 knockdown attenuated
melanoma cell proliferation in vitro. ME2 ablation resulted in reduced cellular ATP levels and elevated cellular
reactive oxygen species production, which activated the AMP-activated protein kinase pathway and inhibited
acetyl-CoA carboxylase. Furthermore, ME2 expression was associated with cell migration and invasion. ME2
knockdown decreased anchorage-independent growth in vitro and tumor cell growth in vivo. These results
suggested that ME2 might be an important factor in melanoma progression and a novel biomarker of invasion.
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INTRODUCTION
Cutaneous melanoma is an aggressive form of skin cancer
that can be cured by removing the tumor at early stages but
becomes deadly once it has progressed to the metastatic stage
(Russo et al., 2009). Recent discoveries of alterations in
several signaling pathways that underlie melanoma
tumorigenesis, such as in the Raf murine sarcoma viral
oncogene homolog B (BRAF), phosphatase and tensin
homolog/PI3K, and p16/Arf pathways, have led to the
development of targeted therapies (Kudchadkar et al.,
2013). For instance, BRAF and MAPK/ERK kinase inhibitors
exhibit notable clinical efficacy in patients with mutant BRAF
(V600E) melanoma; nevertheless, resistance to these agents
usually develops within 6–8 months after initiating treatment,
thereby restricting the survival benefits (Sullivan and Flaherty,
2013). In melanoma, the acquisition of drug resistance after
inhibiting a specific kinase may result from the extensive
redundancy of survival signals transduced by the targeted
kinase (Wilson et al., 2012). Therefore, there is an urgent
need to identify other therapeutic agents that target key
effector molecules that can be used to treat advanced mela-
noma and BRAF wild-type melanoma. An important hallmark
of tumor progression is altered metabolism; the field of cancer
metabolism is currently undergoing a renaissance, with a
rapidly increasing number of studies uncovering connections
between oncogenic pathways and cell metabolism (Qin et al.,
2010; Dang et al., 2011; Zhao et al., 2013). Thus, targeting
tumor metabolism is an appealing strategy for the treatment of
advanced melanoma.
Malic enzymes (MEs) are oxidative decarboxylases that
catalyze the oxidative decarboxylation of L-malate to yield
CO2 and pyruvate while simultaneously reducing NAD(P)
þ to
NAD(P)H (Baggetto, 1992). These enzymes are widely
distributed in nature and have highly conserved sequences
and similar structural topologies across different species,
suggesting that they have important, yet elusive, biological
functions (Chang and Tong, 2003). Three isoforms of ME have
been identified, and these isoforms have been classified on the
basis of their cofactor specificities and subcellular localiza-
tions: cytosolic NADPþ–dependent ME (ME1), mitochondrial
NAD(P)þ–dependent ME (ME2), and mitochondrial NADPþ–
dependent ME (ME3).
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Our laboratory has reported the detailed connection
between the structural topology and the enzyme kinetics of
MEs (Su et al., 2009; Hsieh et al., 2009a,b,c). However, there
is a paucity of knowledge on the metabolic role of MEs in
tumorigenesis. In a rat tracheal epithelial line, the induction
of mitochondrial ME activity occurs early in neoplastic
progression (Wasilenko and Marchok, 1985). Similar
results were observed in Morris hepatomas (Sauer et al.,
1980). Recent studies have shown that ME2 interferes
with the differentiation of erythroleukemia cells (Ren et al.,
2010). In addition, ME2 negatively regulates p53 and is
negatively regulated by p53, forming a feedback loop
involving p53-dependent cellular senescence and ME2-
mediated metabolic rewiring (Jiang et al., 2013). These
observations have suggested that ME2 is involved in tumor
development. Herein, we validated the roles of ME2 in
mediating metabolic alterations in cutaneous melanoma and
evaluated whether ME2 was involved in tumor progression
and invasion.
RESULTS
ME2 mRNA levels were increased and ME1 and ME3 mRNA
levels were decreased in melanoma
To investigate the expression levels of MEs in various stages of
melanoma progression, we analyzed the expression of the
three ME isoforms using two microarray data sets, GDS1375
(Talantov, 2005) and GDS1989 (Smith et al., 2005), from
the NCBI Gene Expression Omnibus (GEO) database. The
samples were classified into two groups: normal skin or
benign nevi (normal/benign) and malignant melanoma (MM,
melanoma). The ME2 mRNA levels were significantly higher
in melanoma than in normal/benign tissue in both data sets
(Figure 1b). In contrast, the ME1 and ME3 mRNA levels were
decreased in the melanoma samples compared with the
normal/benign group in the GDS1375 data set (Figure 1a
and c); however, no significant differences were observed in
the GDS1989 data set.
ME2 protein levels increased with melanoma progression
Because ME2 gene expression was higher in melanoma in
both GEO data sets (Figure 1b), we aimed to ascertain the
clinical relevance of ME2 in melanoma. We performed
immunohistochemistry analysis to assess ME2 protein expres-
sion in common melanocytic nevi, dysplastic nevi, and MM
along with ME1 as an isoform negative control; adjacent
sections were stained with hematoxylin and eosin (Figure 2a).
There was a correlation between higher ME2 protein expres-
sion and disease progression, yet ME1 showed no staining in
MM samples. ME2 expression was significantly upregulated in
MM compared with common melanocytic nevi and dysplastic
nevi (Figure 2b, both Po0.0001). Notably, dysplastic nevi,
which are also known as atypical moles, are more susceptible
to becoming MMs than benign nevi and exhibited weak ME2
expression that was slightly stronger than the staining in the
common melanocytic nevi samples (Figure 2b, P¼ 0.0372).
This result was consistent with the mRNA expression pre-
sented in Figure 1b. ME2 expression did not differ between
primary and metastatic melanoma samples (Supplementary
Figure S1a online). Overall survival was analyzed by dividing
the patients into two groups based on the median total
immunohistochemical intensity score. The survival rate
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Figure 1. ME1 and ME3 mRNA levels were decreased and ME2 mRNA levels
were increased in melanoma compared with normal/nevi tissue in Gene
Expression Omnibus (GEO) data sets. The values of ME1 (a), ME2 (b), and ME3
(c) expression levels in the microarray data sets GDS 1375 and GDS 1989,
which were retrieved from the GEO. Two groups (benign and malignant) of
the data were analyzed using unpaired Student’s t-test. The bars represent
the 95th and 5th percentiles (*Po0.05; ***Po0.001; NS, not significant).
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was not significantly different between the two groups
(Supplementary Figure S1b online). Intriguingly, ME2 expres-
sion levels were significantly higher in acral lentiginous mela-
noma (ALM) samples than in non-ALM samples (Figure 2c).
Depletion of endogenous ME2 levels by small hairpin RNA
(shRNA) impaired melanoma cell proliferation
Because ME2 mRNA and protein expression levels were
increased in the clinical samples, we examined the mRNA
levels of the three ME isoforms in three melanoma cell lines
A375, A2058, and MeWo. Consistent with the data presented
in Figure 1, we determined that all of the three cell lines
expressed higher mRNA levels of ME2 than of ME1 or ME3
(Figure 3a). To investigate the effects of ME2 on melanoma
cell growth, two ME2 knockdown stable clones were
established (Figure 3b) without disrupting ME1 and ME3
expression (Figure 3c). As expected, the proliferation of
A375 and A2058 melanoma cell lines was markedly attenu-
ated by ME2 shRNA (shME2) (Figure 3d). Similarly, BrdU
incorporation in A2058 cells was diminished by ME2 shRNA
(25.3%) compared with control shRNA (shCTRL) (52.4%;
Figure 3e).
Mechanisms of AMP-activated protein kinase (AMPK) activation
induced by ME downregulation
ME2 catalyzes an oxidative decarboxylation reaction conco-
mitant with the conversion of NADþ into NADH, which is the
reducing equivalent for ATP production in subsequent oxida-
tive phosphorylation (Chang and Tong, 2003). Therefore, we
tested the effect of ME2 on ATP production in melanoma cells.
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Figure 2. ME2 expression increased with melanoma tumor progression. (a) Representative hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining
for ME2 in human common nevi, dysplastic nevi, and malignant melanoma tissue sections. The inset is to show stained cells at lower magnification. (b) Scatter
dot plot of the distribution of ME2 expression score in samples at different stages during melanoma development. (c) ME2 IHC score in acral lentiginous
melanoma (ALM) and non-ALM. Inset bar¼ 100mm.
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ME2 knockdown diminished cellular ATP levels in A2058
(Figure 4a) and A375 (Supplementary Figure S2a online) cells.
Consistent with previous studies in erythroleukemia cells (Ren
et al., 2010), reducing ME2 levels increased reactive oxygen
species (ROS) production in A2058 (Figure 4b), A375, and
MeWo (Supplementary Figure S2b online) cells. AMPK is one
of the central energy gauges in eukaryotes and is acti-
vated when intracellular ATP levels decrease (Mihaylova
and Shaw, 2011). ROS have been shown to induce AMPK
activity (Park et al., 2006; Farfariello et al., 2012). Therefore,
we evaluated AMPK activity after depleting ME2. Diminished
ME2 expression increased AMPK phosphorylation at threonine
172, which in turn inhibited acetyl-CoA carboxylase activity
via phosphorylation at serine 79 (Figure 4c). AMPK induction
also activates p53, which promotes metabolic cell cycle arrest
under conditions of glucose deprivation (Jones et al., 2005).
We observed that knocking down ME2 expression activated
AMPK, which resulted in the activation of p53 and its
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Figure 3. The effect of ME2 inhibition on melanoma cell proliferation. (a) ME1, ME2, and ME3 mRNA expression, as measured by reverse transcription–PCR in
the three indicated cell lines. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (b) Western blot analysis shows the
efficacy and selectivity of the small hairpin RNA (shRNA)-lentiviral approach used to silence ME2 expression. a-Actinin was used as a loading control. (c) Cells
treated with control (shCTRL) or ME2 shRNA (shME2) were seeded (2 104) in 24-well plates, and the cell numbers were measured at the indicated time points.
(d) A2058 cells were exposed to 10mM BrdU for an hour, and BrdU incorporation into the DNA was assayed. The marked regions were used to quantify the
percentage of cells capable of BrdU incorporation, which indicated that the cells were progressing through S phase.
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downstream target p21 (Figure 4c). By contrast, the forced
expression of ME2 decreased AMPK phosphorylation and
repressed p53 expression (Figure 4d).
ME2 silencing reduced melanoma cell migration and invasion
To determine the effects of ME2 on melanoma cell migration
and invasion, we performed wound healing and invasion
assays and observed that ME2 expression enhanced cell
migration and invasion (Figure 5a and b). The significance
was further supported by the analysis of the GDS3966 data set
(Xu et al., 2008) from the GEO database (Supplementary
Figure S3 online).
ME2 knockdown attenuated the tumorigenic potential of
melanoma cells
To evaluate the influence of ME2 on the tumorigenic potential
of melanoma cells, A2058 cells expressing shRNA against
ME2 were seeded and grown in soft agar. Reduced ME2
expression resulted in decreased anchorage-independent
growth of A2058 cells (Figure 6a). To further assess the role
of ME2 in vivo, ME2-depleted and control A2058 cells were
implanted into immunocompromised mice; ME2 depletion
significantly delayed tumor growth in vivo (Figure 6b), and
efficient ME2 knockdown was confirmed by western blot
analysis (Figure 6c). In agreement with findings in U2OS and
HCT116 cells (Jiang et al., 2013), depletion of ME2 decreased
the volume and weight of A2058 tumor xenografts.
DISCUSSION
Until recently, few studies have shown a significant role for
ME2 in human cancer (Sauer et al., 1980; Moreadith and
Lehninger, 1984; Ren et al., 2010). In this study, we demon-
strated that ME2 expression increased significantly during
melanoma progression. We determined that ME2 has an
important role in cell growth, which may be partially
because of its regulation of the AMPK pathway. Our studies
revealed that ME2 expression influenced melanoma cell
migration and invasion, which was possibly related to the
required energy supply for cell mobility. These findings support
a functional role for ME2 in cutaneous melanoma progression.
However, ME2 expression was not associated with overall
survival or metastasis in melanoma patient samples. ME2
upregulation, similar to the M2 isoform of pyruvate kinase
(PKM2), could be an early event in melanoma tumorigenesis
that functions as a licensing factor to support the altered energy
demands for cell transformation (Tamada et al., 2012).
Acral lentiginous melanoma is an invasive subtype of
melanoma that is rare in the Caucasian population but often
occurs in Asian and Black populations (Bradford et al., 2009).
Our tissue microarrays were composed of samples from
Taiwanese people, who account for more than half of the
patients with ALM. We demonstrated that ME2 expression was
higher in ALM samples than in non-ALM samples. This result
supported the functional role of ME2 in cell invasion. The
detailed mechanism by which ME2 expression is upregulated in
ALM remains unclear; further studies on the connection bet-
ween distinct gene alterations in different melanoma subtypes
and ME2 expression will elucidate the role of ME2 in response
to metabolic changes during tumor development (Curtin et al.,
2005). On the basis of our data, the development of agents
targeting ME2 could be an appealing strategy for treating ALM.
Tumor cells alter their metabolic patterns to satisfy the
needs of rapid cell proliferation. Aerobic glycolysis, also
known as the Warburg effect, is enhanced glycolysis, irre-
spective of the presence of oxygen, that is initiated to produce
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Figure 4. AMP-activated protein kinase (AMPK) activation as the mechanism
for melanoma cell growth inhibition in response to ME2 depletion.
(a) Silencing ME2 diminished ATP production in melanoma cells. ATP levels
in A2058 cells were measured and normalized to the respective protein
concentration. (b) Increased reactive oxygen species levels in A2058
ME2-knockdown cells as determined by flow cytometry using 2’,7’-
dichlorodihydrofluorescein diacetate (DCF). Each histogram is representative of
three independent experiments. (c) Western blot analysis was used to
determine the protein levels of p-AMPK (Thr172), total AMPK, acetyl Co-A
carboxylase (ACC), p53, and p21. Phospho Ser-79 ACC is a biomarker of
AMPK activity. (d) Western blot of p-AMPK, total AMPK, ACC, p53, and p21 in
indicated melanoma cell lines transfected with control vector or with ME2-
expressing vector. The level of ME2 protein after normalization with a-actinin
is presented as fold change.
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sufficient nutrients for cancer cell growth and division. The
shortage of pyruvate from glycolysis is replenished by gluta-
minolysis for mitochondria anaplerosis, in which MEs partici-
pate to generate sufficient energy for rapid cell proliferation
(vander Heiden et al., 2009). Advances in molecular biology
have revealed how oncogene or tumor-suppressor signaling
affects metabolic profiles during tumorigenesis, such as by
rapidly increasing ATP production to sustain the energy status,
enhancing macromolecular biosynthesis, and maintaining
the proper cellular redox state (Cairns et al., 2011). A recent
study showed that ME2 and p53 mutually negatively regulate
one another, implying that ME2 might exhibit oncogenic
properties, opposite to p53 (Jiang et al., 2013). In the
present study, we consistently observed that ME2 depletion
in A375 cells (harbors wild-type p53) enhanced AMPK
activity, increased p53 levels, and upregulated the p53 down-
stream target p21, which inhibits the cell cycle. Conversely,
overexpressing ME2 decreased p53 expression and AMPK
activity. No induction of p21 expression in response to ME2
silencing was observed in A2058 cells may result from its p53
status (V274F), which is a loss of transactivation mutant.
Reduced cellular anabolism, such as lipid biosynthesis, in
response to activated AMPK signaling may be the reason why
knocking down ME2 expression suppressed cell growth.
Metformin inhibits melanoma cell invasion and metastasis in
an AMPK/p53-dependent manner (Cerezo et al., 2013). In
light of this, the reduced melanoma cell invasion and mobility
in response to ME2 silencing was potentially a result of AMPK
activation and p53 upregulation.
A recent study revealed that BRAF inhibitors enhanced
mitochondrial oxidative phosphorylation capacity in BRAF
mutant melanoma through enhanced levels of microphthalmia-
associated transcription factor and PGC1a, which is the
mitochondrial master transcription regulator (Haq et al.,
2013). Different BRAF status between melanoma cells may
exert different mitochondrial metabolic profiles, yet we
found that A375 and A2058 (both harbor BRAF V600E) and
MeWo (wild-type BRAF) exhibit similar expression patterns in
the three isoforms of MEs. Moreover, ME2 expression levels
remained unchanged in response to BRAF inhibitor treatment
in a dose-dependent manner (Supplementary Figure S4a
online). In terms of intratumor heterogeneity, phenformin
selectively targets JARID1B-positive melanoma cells, which
are slow-cycling melanoma cell subpopulations, whereas
BRAF inhibitor selectively targets the JARID1B-negative sub-
population of melanoma cells (Roesch et al., 2013; Yuan
et al., 2013). We examined the effect of ME2 silencing, similar
to AMPK activators such as phenformin, in combination
with BRAF inhibitor on melanoma cell viability. Knockdown
of ME2 in melanoma cells did not increase the sensitivity
of A375 and A2058 cells to BRAF inhibitor (Supplementary
Figure S4b and c online). Compared with single-gene silencing,
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phenformin may exert its synergistic effect with BRAF inhibitor
through more mechanisms, such as suppressing the transfor-
mation of cells from the JARID1B-negative to JARID1B-
positive phenotype (Yuan et al., 2013), AMPK-independent
mTOR inhibition (Kalender et al., 2010), and suppressing
oxidative phosphorylation (Pollak, 2013).
Whether ME2 enzyme activity is required for its effects on
AMPK and p53 remains unclear. Recently, nonenzymatic
functions of metabolic enzymes have garnered much attention
in cancer metabolism research. For instance, the M2 isoform
of pyruvate kinase (PKM2), which forms a tetramer in the
cytosol, is the final key enzyme in aerobic glycolysis. How-
ever, PKM2 can translocate into the nucleus to act as a protein
kinase in its dimeric form and phosphorylate signal transducer
and activator of transcription 3 (Gao et al., 2012) or to directly
interact with HIF1-a to promote downstream target transacti-
vation (Luo et al., 2011). The possibilities of different
subcellular localizations, conformations, and nonenzymatic
functions of ME are worthy of further investigation.
The cross talk between the three ME isoforms and their
physiological roles in cancer metabolism remain undefined.
Our data revealed that cells prefer to enhance metabolic flow
through ME2, rather than through ME1 and ME3, via tran-
scriptional regulation during melanoma progression. One
possible reason for this pattern is that ME2 possesses dual
cofactor specificity, requiring either NADþ or NADPþ , and it
is localized to the mitochondria. In terms of the Warburg
effect, aerobic glycolysis redirects pyruvate from glycolysis to
lactate production, resulting in a pyruvate shortage in the
mitochondria, and ME2 maintains constant anaplerosis by
replenishing pyruvate from glutamine to sustain the tricar-
boxylic acid cycle or to produce acetyl-CoA for lipid biosynth-
esis. In contrast, the pyruvate produced by ME1 may be
readily converted to lactate in its cytosolic location. Further-
more, several lines of evidence indicate that ME2 uses two
cofactors, NADþ or NADPþ , to produce NADH or NADPH
(Chang and Tong, 2003; Hsieh et al., 2006), which are the
reducing agents for ATP production and ROS clearance,
respectively. In agreement with this hypothesis, ME2
knockdown reduced ATP production and increased ROS
levels in melanoma cells. Although it is known that ROS are
mainly produced from oxidative phosphorylation during ATP
synthesis, the effects of ME2 depletion may have a greater
impact on ROS clearance (reduced NADPH) than on ROS
generation (reduced ATP synthesis). Moreover, of the three ME
isoforms, only ME2 is inhibited by ATP, implying that it may
be an energy gauge for cell metabolism (Hsu et al., 2004;
Hung et al., 2005; Hsieh et al., 2008). In addition, a recent
study showed that suppressing ME2 expression reduced
NADPH production and decreased triacylglycerol synthesis
more significantly than ME1 depletion (Jiang et al., 2013).
Taken together, substantial evidence suggests that the dual
cofactor that is characteristic of ME2 may make this enzyme a
key switch to meet the metabolic demands of rapidly
proliferating cancer cells.
MATERIALS AND METHODS
Gene Expression Omnibus data sets
Two GEO data sets GDS1375 and GDS1989 were used in this study.
GDS1375 contains 25 normal/benign nevi and 45 melanoma speci-
mens, and ME mRNA expression values retrieving from [GDS1375/
204059_s_at/ME1], [GDS1375/209397_at/ME2], and [GDS1375/
204663_at/ME3] were subjected to statistical analysis. Similar to
GDS1989, 8 normal/nevi samples and 10 melanoma samples pre-
sented in [GDS1989/204059_s_at/ME1], [GDS1989/210153_s_at/
ME2], and [GDS1989/204663_at/ME3] were collected and subjected
to statistical analysis.
Tissue microarrays and immunohistochemistry
All human tissue materials included in this study were obtained under a
research protocol approved by the Institutional Review Board of
Tri-Service General Hospital, National Defense Medical Center
(TSGHIRB-098-05-216, 1999). Written informed consent for paraffin
block experiments was not required because ROC laws considered
human tissue left over from routine surgery as discarded material before
2011. The establishment of tissue microarray slides has been described
previously (Gao et al., 2010). The sections were deparaffinized,
rehydrated, and subjected to antigen retrieval and peroxidase
inactivation. Slides were blocked with Power Block (Biogenex,
Fremont, CA) and then incubated with an anti-human ME2 or ME1
antibody (1:75; both from Abcam, Cambridge, MA) for 1 hour and with
biotin-labeled secondary immunoglobulin (1:100; DAKO, Carpinteria,
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Figure 6. ME2 depletion reduced anchorage-independent growth and
attenuated tumor growth in a xenograft model. (a) Anchorage-independent
growth of ME2 knockdown and control A2058 cells in a soft agar assay.
Colonies 40.1mm were counted using ImageJ, and the data were plotted
(right panel). The data are presented as the mean±SD of triplicate samples
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of ME2 expression in representative specimens.
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CA) for 1 hour. After development with the AEC chromogenic system
(DAKO), the sections were counterstained with hematoxylin and
mounted. The immunostaining intensity was classified as grade 0
(absent), grade 1 (weak), grade 2 (moderate), or grade 3 (strong) by light
microscopy. The percentage of tumor cells in each section was also
quantified. The percentage of ME2-positive cells was multiplied by
their average immunostaining intensity, producing a final immuno-
staining score between 0 and 300. The slides were scored by two
independent investigators, and the results were compared with identify
bias and to maintain consistency.
Cell culture and gene silencing
The melanoma cell lines were grown in DMEM medium (A375 and
A2058) or DMEM/F12 (MeWo) supplemented with 10% fetal bovine
serum at 37 1C and 5% CO2. The shRNA lentiviral vectors targeting
human ME2 (Clone ID: #1:TRCN0000286588 and #2:
TRCN000294005) and a pLKO.1 control lentiviral vector were
purchased from the National RNAi Core Facility, Academia Sinica,
Taiwan. Cells infected with lentivirus-containing target gene shRNAs
were selected in 1.0mg ml 1 puromycin. Pooled populations of
knockdown cells were used for the experiments.
Cell counting, proliferation assays, and reactive oxygen species
detection
Control and ME2-deficient cell lines were seeded in 24-well plates
(1 104 cells/well). After 24, 48, or 72 hours, the cells were
trypsinized and counted using a Coulter counter. All samples were
analyzed in triplicate to generate proliferation curves. The prolifera-
tion rate of A2058 cells (1 106) was determined using a FITC BrdU
Flow Kit according to the manufacturer’s instructions (559619, BD
Biosciences, San Jose, CA). ROS production was evaluated as follows.
Cells (5 105) were rinsed with phosphate-buffered saline (PBS) and
incubated in serum-free DMEM containing DCFH-DA (Sigma-
Aldrich, St Louis, MO) for 30 minutes. Next, the cells were trypsinized
and washed with PBS. After resuspension in 100ml of PBS, the
cellular ROS levels were determined by flow cytometry.
Reverse transcription–PCR
Total RNA was isolated from cells using a total RNA reagent (Bioman,
Taiwan, ROC). One microgram of RNA was reverse transcribed into
cDNA using MMLV reverse transcriptase (Epicentre Biotechnologies,
Madison, WI). PCR was performed in the linear range (25 cycles) with
primers specific for ME1, ME2, and ME3. The primer sequences used
to amplify the target genes were as follows: ME1 upper, 50-ACCCTGG
AAGAGAGACAGCA-30; ME1 lower, 50-CCAATTTACCCACAGGG
ATG-30; ME2 upper, 50-AGAGCTAGCCCAAGGGAGAC-30; ME2
lower, 50-TCAACACGTCTACCCCAACA-30; ME3 upper, 50-CCCTATC
ATCTTTGCCCTGA-30; and ME3 lower, 50-GGAAGCCAGGTTGTGT
TTGT-30.
Western blot analysis
Cells were lysed and homogenized in RIPA buffer at 4 1C, and the
proteins were separated by SDS-PAGE. After transferring the proteins
to a polyvinylidine difluoride membrane (Millipore, Bedford, MA),
the proteins were detected using antibodies against alpha-actinin
(ACTN), p53, p21 (Santa Cruz Biotechnology, Santa Cruz, CA), ME2
(Sigma-Aldrich), and AMPK and acetyl Co-A carboxylase antibody
sampler kit (Cell Signaling, Beverly, MA).
ATP assay
Cells (1 106) were analyzed for cellular ATP levels using an ATP
Colorimetric Assay Kit (BioVision, Milpitas, CA) according to the
manufacturer’s protocol.
Cell migration and invasion assay
Briefly, cells were grown to confluence and then wounded with a
pipette tip. The recovered area was measured after the indicated time
in serum-free medium. For invasion assays, 104 cells were plated on
top of the invasion chambers (BD Biosciences, San Jose, CA), which
were coated with a thin layer of Matrigel matrix, and transferred to
wells with medium containing 5% serum as the chemoattractant. The
cells on the lower surface of the chamber membrane were stained
using crystal violet.
Soft agar assay
Cell suspensions (5 103) were incubated in an upper layer of 0.35%
agarose (Invitrogen, Grand Island, NY) in DMEM with 10% fetal
bovine serum. The suspension was overlaid onto 0.5% basal agar
with 10% fetal bovine serum in a six-well plate and placed at room
temperature until the agarose solidified. The plates were transferred to
a 5% CO2 incubator and were incubated at 37 1C for 2 weeks before
being stained with crystal violet. Colonies larger than 0.1 mm in
diameter were counted using ImageJ (NIH, Bethesda, MD).
In vivo xenograft experiments
A2058 cells infected with vector or shME2 lentivirus were injected
subcutaneously into the left and right flanks of 5-week-old female
immunodeficient (NOD/SCID) mice at 2 106 cells per mouse in
0.1 ml of sterile PBS, respectively. The tumor weights were measured
2 weeks later. All of the experiments were performed according to the
ethical guidelines for laboratory animal use and were approved by the
Institutional Animal Care and Use Committee at the National Defense
Medical Center, Taiwan (ROC).
Statistical analysis
The means and standard deviations (SD) were calculated and plotted
using GraphPad Prism (version 6; GraphPad Software, La Jolla, CA).
Simple comparisons were made by using unpaired Student’s t-test
unless otherwise indicated.
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